Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for leuprorelin acetate

  1. Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

    Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA832

  2. Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]

    In development [GID-TA11131] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued [GID-TA10377]

    Technology appraisal guidance
    Discontinued

  4. Research recommendations

    diagnosed epilepsy? Focal seizures: carbamazepine, eslicarbazepine acetate, lacosamide, lamotrigine, levetiracetam, pregabalin and...